[go: up one dir, main page]

MX2019012189A - Metodos para valorar la glucosilacion de la superficie celular. - Google Patents

Metodos para valorar la glucosilacion de la superficie celular.

Info

Publication number
MX2019012189A
MX2019012189A MX2019012189A MX2019012189A MX2019012189A MX 2019012189 A MX2019012189 A MX 2019012189A MX 2019012189 A MX2019012189 A MX 2019012189A MX 2019012189 A MX2019012189 A MX 2019012189A MX 2019012189 A MX2019012189 A MX 2019012189A
Authority
MX
Mexico
Prior art keywords
methods
assessing
cell surface
glycans
cell
Prior art date
Application number
MX2019012189A
Other languages
English (en)
Inventor
Mirna Mujacic
Tom Kowski
Paul Ken Kodama
Kenneth Mayo Prentice
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of MX2019012189A publication Critical patent/MX2019012189A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01052—Peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase (3.5.1.52), i.e. glycopeptidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en el presente documento métodos para valorar los glicanos de la superficie celular, por ejemplo, los N-glicanos, valorando una muestra de los glicanos liberados de la superficie, y determinando la presencia, la ausencia o el nivel de glicanos presentes en la muestra.También se proporcionan métodos para probar y/o evaluar una composición celular valorando el perfil de los glicanos de la superficie celular de la composición celular y comparando el perfil con una muestra de referencia. También se proporcionan métodos para fabricar y/o cultivar una pluralidad de composiciones celulares que tienen una expresión consistente de los glicanos de la superficie con baja variabilidad.
MX2019012189A 2017-04-14 2018-04-13 Metodos para valorar la glucosilacion de la superficie celular. MX2019012189A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485897P 2017-04-14 2017-04-14
US201762515515P 2017-06-05 2017-06-05
PCT/US2018/027666 WO2018191723A1 (en) 2017-04-14 2018-04-13 Methods for assessing cell surface glycosylation

Publications (1)

Publication Number Publication Date
MX2019012189A true MX2019012189A (es) 2020-12-10

Family

ID=62196676

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012189A MX2019012189A (es) 2017-04-14 2018-04-13 Metodos para valorar la glucosilacion de la superficie celular.

Country Status (9)

Country Link
US (3) US11796534B2 (es)
EP (1) EP3610261A1 (es)
JP (1) JP7355650B2 (es)
CN (1) CN110709700A (es)
AU (1) AU2018251188A1 (es)
CA (1) CA3059584A1 (es)
MA (1) MA54103A (es)
MX (1) MX2019012189A (es)
WO (1) WO2018191723A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015249554B2 (en) 2014-04-23 2021-08-19 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
MA54103A (fr) 2017-04-14 2021-09-15 Juno Therapeutics Inc Procédés d'évaluation de la glycosylation de surface cellulaire
PL3704230T3 (pl) * 2017-11-01 2025-02-24 Juno Therapeutics, Inc. Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie
US12366580B2 (en) * 2018-09-11 2025-07-22 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
CN109884203B (zh) * 2019-03-07 2022-02-22 通化东宝药业股份有限公司 一种氯乙酰肼的检测方法和一种检测磷酸西格列汀中氯乙酰肼的方法

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
JPH083487B2 (ja) 1987-07-31 1996-01-17 株式会社日本抗体研究所 異常応答リンパ球の検出方法並びにこれに用いる検出用試薬及びキット
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
DK0472651T4 (da) 1989-05-16 2007-03-05 Genzyme Corp Endo F-frit PNGase
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
JP2001519143A (ja) 1997-10-02 2001-10-23 スノル・モレキュラー・コーポレーション 可溶性の一本鎖ｔ細胞レセプタータンパク質
RU2149023C1 (ru) 1998-04-20 2000-05-20 Ерхов Валентин Сергеевич Способ получения специфической антисыворотки к универсальному опухолевому антигену и способ диагностики злокачественных опухолей с использованием этой антисыворотки
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2001094944A2 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
ATE290020T1 (de) 2001-08-31 2005-03-15 Avidex Ltd Löslicher t zell rezeptor
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
JP2009103718A (ja) 2002-09-02 2009-05-14 National Agriculture & Food Research Organization ビオチン化タンパク質を用いる受容体チップおよびその作製方法
DE60333500D1 (de) 2002-10-02 2010-09-02 Hoffmann La Roche Verfahren zur Identifizierung antigener Peptide
EP1549748B1 (en) 2002-10-09 2014-10-01 Immunocore Ltd. Single chain recombinant t cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2005050188A1 (ja) 2003-11-21 2005-06-02 Eisai Co., Ltd. 同位体標識化内部標準物質を用いる定量方法、該定量方法を実行する解析システムおよび該解析のためのプログラム
CA2567814C (en) 2004-05-27 2013-07-23 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
AU2006268559B2 (en) 2005-07-11 2012-11-29 Glykos Finland Oy Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
US7653496B2 (en) 2006-02-02 2010-01-26 Agilent Technologies, Inc. Feature selection in mass spectral data
EP2856876B1 (en) 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EA009326B1 (ru) 2007-04-06 2007-12-28 Петр Генриевич ЛОХОВ Способ определения качества клеточной культуры
EP2511705A1 (en) * 2007-04-16 2012-10-17 Momenta Pharmaceuticals, Inc. Methods related to cell surface glycosylation
CA2682695A1 (en) 2007-04-16 2008-10-30 Momenta Pharmaceuticals, Inc. Characterization of n-glycans using exoglycosidases
CN101784670A (zh) 2007-08-31 2010-07-21 弗·哈夫曼-拉罗切有限公司 糖基化谱分析
DK2520643T3 (da) 2007-12-07 2020-01-20 Miltenyi Biotec Bv & Co Kg Prøvebehandlingssystemer og -fremgangsmåder
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
JP2009142238A (ja) * 2007-12-18 2009-07-02 Sumitomo Bakelite Co Ltd 細胞表面糖鎖の遊離方法及び検出方法
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
IT1391942B1 (it) 2008-11-14 2012-02-02 Polimeri Europa Spa Procedimento per l'ottenimento di un elastomero in fase solida a partire dalla sua soluzione polimerica
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
CA2779526C (en) 2009-11-03 2022-12-06 City Of Hope Truncated epiderimal growth factor receptor (egfrt) for transduced t cell selection
JP2013100233A (ja) * 2010-02-26 2013-05-23 Osaka Prefectural Hospital Organization 腫瘍マーカー、それに対する抗体、その検出キット及びその検出方法
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2651442B1 (en) 2010-12-14 2020-04-22 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
EA201391449A1 (ru) 2011-04-01 2014-03-31 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела против пептидов цитозоля
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
JP6051594B2 (ja) * 2011-05-20 2016-12-27 国立大学法人 大分大学 糖質プロファイリングによる血液腫瘍診断のための診断基準を得る方法
CN103842818B (zh) 2011-09-28 2018-09-21 沃特世科技公司 具有增强的ms信号的聚糖和其它生物分子的快速荧光标记
ES2687954T3 (es) 2011-11-11 2018-10-30 Fred Hutchinson Cancer Research Center Inmunoterapia de linfocitos T dirigidos a ciclina A1 contra el cáncer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
RU2018130123A (ru) 2012-05-03 2018-11-07 Фред Хатчинсон Кансэр Рисёч Сентер Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
CN104853766A (zh) 2012-10-02 2015-08-19 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
WO2014097442A1 (ja) 2012-12-20 2014-06-26 三菱電機株式会社 車載装置及びプログラム
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
JP6169552B2 (ja) * 2013-10-01 2017-07-26 Ｊｃｒファーマ株式会社 ２−アミノピリジンによる糖鎖の標識法
GB201320571D0 (en) * 2013-11-21 2014-01-08 Academisch Ziekenhuis Leiden Glycan analysis
AU2015249554B2 (en) 2014-04-23 2021-08-19 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2016036705A1 (en) * 2014-09-03 2016-03-10 Musc Foundation For Research Development Glycan panels as specific tumor tissue biomarkers
CA3000514A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
MA54103A (fr) 2017-04-14 2021-09-15 Juno Therapeutics Inc Procédés d'évaluation de la glycosylation de surface cellulaire
US12366580B2 (en) 2018-09-11 2025-07-22 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions

Also Published As

Publication number Publication date
EP3610261A1 (en) 2020-02-19
JP2020516892A (ja) 2020-06-11
MA54103A (fr) 2021-09-15
US11796534B2 (en) 2023-10-24
JP7355650B2 (ja) 2023-10-03
CN110709700A (zh) 2020-01-17
CA3059584A1 (en) 2018-10-18
US20240159743A1 (en) 2024-05-16
US12379375B2 (en) 2025-08-05
US20210255173A1 (en) 2021-08-19
US20250290918A1 (en) 2025-09-18
WO2018191723A1 (en) 2018-10-18
AU2018251188A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
MX2019012189A (es) Metodos para valorar la glucosilacion de la superficie celular.
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
DK3583214T5 (da) Fremgangsmåder og sammensætninger til identificering eller kvantificering af mål i en biologisk prøve
MX392706B (es) Ensayo a base de células para detectar homodímeros anti-cd3.
BR112015022490A2 (pt) métodos e composições para classificação de amostras
GB201305388D0 (en) Benchmarks for normal cell identification
MX2016016076A (es) Composiciones de celulas t mejoradas.
IN2014CN01970A (es)
EP2673589A4 (en) TOLERANCE ASSESSMENT WITH REDUCED MEASURED POINTS
IL290245A (en) Single cell analysis
MX2017009768A (es) Ligadores lábiles para detección de biomarcadores.
WO2020087037A3 (en) Disease stratification of liver disease and related methods
NZ621733A (en) Lung cancer biomarkers and uses thereof
HK1202625A1 (en) Compositions and methods for assessing appendicitis
MX2017000083A (es) Compuestos de platino, composiciones y usos de estos.
WO2014186761A3 (en) Methods for determining responsiveness to an anti-cd47 agent
CO2017005773A2 (es) Composiciones, dispositivos, y métodos de pruebas de sensibilidad del ibs
WO2011106709A3 (en) Epithelial biomarkers for cancer prognosis
ES2531137T3 (es) Clasificación de señales de audio basada en marcos
EP4614153A3 (en) Cancer biomarkers
MX375421B (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
ZA202001214B (en) Systems and methods for performing a real-time glycan assay of a sample
MX2017014247A (es) Metodos para valorar la pureza de una preparacion de celulas germinales mesenquimales.
MX2017012758A (es) Metodo y aparato para estimar la cantidad de microorganismos en una unidad taxonomica en una muestra.
EP4116713A3 (en) Compositions, devices, and methods of osteoarthritis sensitivity testing